BOCA RATON, FL--(Marketwire - September 16, 2008) - Vicor Technologies, Inc. (OTCBB: VCRT) today announced publication of the results of its first clinical study conducted in collaboration with the U.S. Army Institute of Surgical Research (USAISR). Vicor Technologies is a biotechnology company that has developed the PD2i, a patented, proprietary algorithm that is now in trials for FDA 510(k) approval for a) measuring heart rate variability (PD2i Analyzer), b) risk stratifying combat and civilian trauma victims (PD2i VS), and c) identifying patients at risk of suffering sudden cardiac death (PD2i CA).
